- Home
- FR vs NUVL Comparison
FR vs NUVL Comparison
Compare FR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FR
- NUVL
- Stock Information
- Founded
- FR 1993
- NUVL 2017
- Country
- FR United States
- NUVL United States
- Employees
- FR N/A
- NUVL N/A
- Industry
- FR Real Estate Investment Trusts
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- FR Real Estate
- NUVL Health Care
- Exchange
- FR Nasdaq
- NUVL Nasdaq
- Market Cap
- FR 6.9B
- NUVL 5.8B
- IPO Year
- FR 1994
- NUVL 2021
- Fundamental
- Price
- FR $51.89
- NUVL $79.37
- Analyst Decision
- FR Buy
- NUVL Strong Buy
- Analyst Count
- FR 10
- NUVL 11
- Target Price
- FR $54.80
- NUVL $120.91
- AVG Volume (30 Days)
- FR 883.0K
- NUVL 405.2K
- Earning Date
- FR 10-15-2025
- NUVL 11-11-2025
- Dividend Yield
- FR 3.43%
- NUVL N/A
- EPS Growth
- FR N/A
- NUVL N/A
- EPS
- FR 2.05
- NUVL N/A
- Revenue
- FR $700,534,000.00
- NUVL N/A
- Revenue This Year
- FR $10.66
- NUVL N/A
- Revenue Next Year
- FR $7.30
- NUVL N/A
- P/E Ratio
- FR $25.36
- NUVL N/A
- Revenue Growth
- FR 8.80
- NUVL N/A
- 52 Week Low
- FR $40.31
- NUVL $55.54
- 52 Week High
- FR $58.17
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- FR 55.43
- NUVL 53.39
- Support Level
- FR $51.01
- NUVL $74.40
- Resistance Level
- FR $52.88
- NUVL $83.09
- Average True Range (ATR)
- FR 0.95
- NUVL 3.03
- MACD
- FR -0.03
- NUVL 0.43
- Stochastic Oscillator
- FR 41.27
- NUVL 62.08
About FR First Industrial Realty Trust Inc.
First Industrial Realty Trust Inc is a real estate investment trust that owns, manages, acquires, sells, develops, and redevelops industrial real estate. Through its fully integrated operating and investing platform, the company provides facilities and customer service to multinational corporations and regional firms that are essential for their supply chains. The company serves a diverse tenant base across various sectors, including e-commerce, logistics, transportation, manufacturing, retail, consumer services, food and beverage, building materials, wholesale goods, health services, and government.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.